Keros Therapeutics (KROS) Current Assets (2019 - 2026)
Keros Therapeutics' (KROS) quarterly Current Assets came in at $315.4 million in Q4 2025, down 46.44% YoY from $588.9 million in Q4 2024, and down 56.15% on a QoQ basis from $719.3 million in Q3 2025.
Keros Therapeutics (KROS) Current Assets (2019 - 2026) Analysis & Trends
Keros Therapeutics (KROS) has 7 years of Current Assets data on file, last reported at $315.4 million in Q4 2025.
- Quarterly Current Assets fell 46.44% year-over-year to $315.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $315.4 million (down 46.44% YoY) and the FY2025 annual result came in at $315.4 million, down 46.44% from the prior year.
- Current Assets fell to $315.4 million in Q4 2025, from $719.3 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $759.5 million in Q1 2025 to a low of $222.4 million in Q2 2022.
- A 5-year average of $393.6 million and a median of $324.9 million in 2023 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2021 — Current Assets jumped 337.28% — and 2025, when it slumped 46.44%.
- Tracing KROS's Current Assets over 5 years: stood at $251.4 million in 2021, then gained by 13.65% to $285.8 million in 2022, then grew by 21.53% to $347.3 million in 2023, then soared by 69.57% to $588.9 million in 2024, then tumbled by 46.44% to $315.4 million in 2025.
- The last three Current Assets figures came in at $315.4 million (Q4 2025), $719.3 million (Q3 2025), and $732.8 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.62 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.63 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 1.76 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 18.80 Bn |
| 10 | Keros Therapeutics | 217.21 Mn | -40.40 Mn | - | 266.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 266.88 Mn |
| Dec 31, 2025 | 315.43 Mn |
| Sep 30, 2025 | 719.31 Mn |
| Jun 30, 2025 | 732.81 Mn |
| Mar 31, 2025 | 759.51 Mn |
| Dec 31, 2024 | 588.89 Mn |
| Sep 30, 2024 | 552.05 Mn |
| Jun 30, 2024 | 432.71 Mn |
| Mar 31, 2024 | 463.13 Mn |
| Dec 31, 2023 | 347.29 Mn |
| Sep 30, 2023 | 304.44 Mn |
| Jun 30, 2023 | 334.31 Mn |
| Mar 31, 2023 | 362.22 Mn |
| Dec 31, 2022 | 285.77 Mn |
| Sep 30, 2022 | 245.88 Mn |
| Jun 30, 2022 | 222.36 Mn |
| Mar 31, 2022 | 231.22 Mn |
| Dec 31, 2021 | 251.44 Mn |
| Sep 30, 2021 | 226.07 Mn |
| Jun 30, 2021 | 241.42 Mn |